Disc Medicine (IRON) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

IRON Disc Medicine

Watchlist

27.550
+1.030+3.88%

Close Apr 26 16:00 ET

27.550
0.0000.00%

Post 16:20 ET

679.96MMarket Cap-8055P/E (TTM)

Full Hours

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Disc Medicine(IRON.US) Director Sells US$81,406.83 in Common Stock
$Disc Medicine(IRON.US)$ Director White William Richard sold 2,560 shares of common stock on Apr 11, 2024 at an average price of $31.7995 for a total value of $81,406.83.Source: Announcement What is s
moomoo NewsApr 15 19:08 ET
HROW, HCAT and EGRX Are Among After Hour Movers
Seeking AlphaApr 12 17:05 ET
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), Disc Medicine (IRON) and Avita Medical (RCEL)
TipRanksApr 11 06:20 ET
Express News | Stifel Maintains Buy on Disc Medicine, Raises Price Target to $73
Moomoo 24/7Apr 8 08:44 ET
Analysts Conflicted on These Healthcare Names: Legend Biotech (LEGN), Intuitive Surgical (ISRG) and Disc Medicine (IRON)
TipRanksApr 8 07:20 ET
Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More
Yahoo FinanceApr 4 13:21 ET

Comments

7122413

Apr 2 01:52

$Disc Medicine(IRON.US)$ easy money

Invest with Sarge

Apr 2 00:15

Not Ironman ...

Disc Medicine $Disc Medicine(IRON.US)$ down 55% on Monday.

Meltyy

Jan 3 20:11

Upcoming Ph 2 readouts in Q1 2024…

$Cellectar BioSciences(CLRB.US)$ Phase 2
$Regenxbio(RGNX.US)$ Phase 2
$Leap Therapeutics(LPTX.US)$ Phase 2
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US)$ Phase 2
$Disc Medicine(IRON.US)$ Phase 2
$Atea Pharmaceuticals(AVIR.US)$ Phase 2
$Allakos(ALLK.US)$ Phase 2...

Analysts Notebook

Dec 27, 2023 18:18

ColumnsBiotech Outlook 2024: Analysts Believe the Biotech Sector is Poised for Recovery Next Year

Following a turbulent period, there has been a notable change in the trajectory of biotech stocks. After experiencing significant downturns in 2021 and 2022, the $SPDR S&P Biotech ETF(XBI.US)$ has seen an increase of 5.5% in the current year. However, it continues to trail considerably behind the$S&P 500 Index(.SPX.US)$, which has achieved a 24% gain. However, analysts indicate that the previously cool sent...